4) Targeted Therapy and Personalized Medicine in Oncology: Promises and Pitfalls

The concept of fusion genes where two normally distant genes combine to create a new genome.
This phenomenon can lead to diseases such as cancer, where specific molecular pathways become dysregulated.
PCAV is identified as a driving gene in certain cancers; it's a protein kinase activating various important cellular pathways.
Development of kinase inhibitors has led to novel treatments, which in some cases have been remarkably effective, allowing many patients to manage their disease with just a single pill. Historically, these cancers led to poor prognoses and rapidly fatal outcomes.

Cancer is often not driven by a single gene but involves multiple genetic alterations, particularly in solid tumors.
Genetic changes often occur in a sequential manner, akin to a chain reaction, making it difficult to pinpoint a specific cause or treatment target.
For example, colon cancer is characterized by a sequence of mutations from normal colonic cells progressing through dysplasia to carcinoma. Key genes like APC, KRAS, TP53, and SMAD4 are frequently mutated in colon cancer, emphasizing the complex genetics at play.

Not all cancers with similar names are genetically identical; even identical twins can have different mutations.
Cancer research increasingly recognizes that cancers display significant inter- and intra-tumoral heterogeneity, impacting treatment approaches.

Somatic mutations versus germline mutations: Somatic mutations are acquired changes that drive cancer, while germline mutations are inherited and present in all cells.
Certain cancers exhibit higher mutational burdens, such as melanoma and lung cancer, often linked to environmental factors like UV exposure or smoking.
An understanding of mutation rates is essential as it can inform therapeutic strategies.

The aim of personalized medicine is to tailor treatment based on the specific genetic makeup of a patient's tumor.
Biomarkers play a critical role in classifying tumors into subgroups, which can help predict treatment responses and potential side effects.
Various 'omics' technologies, including genomics, transcriptomics, proteomics, and metabolomics, are at the forefront of this field to provide comprehensive data on tumor characteristics.

The treatment journey begins with biopsy samples from both tumor and normal tissues.
Advanced sequencing technologies (e.g., pyrosequencing) facilitate the analysis of genetic profiles, enabling the identification of mutations driving cancer.
A significant challenge remains the availability of targeted therapies for detected mutations, necessitating ongoing research to discover and validate new drugs.

The development of immune therapies (e.g., checkpoint inhibitors, CAR T-cell therapies) signifies an important shift in cancer treatment, improving responses for many patients.
Tumors evolve under therapeutic pressure, often leading to resistance; understanding these mechanisms is crucial for developing effective treatment combinations.
Clinical trials are essential to determine the efficacy of new therapies, with elaborate testing phases to ensure sufficient evidence for approval and reimbursement.

Therapeutic approaches for lung cancer have evolved to recognize specific genetic mutations, such as EGFR and KRAS, to guide treatment strategies.
EGFR inhibitors have transformed treatment plans, especially for patients with particular mutations. The emergence of single-agent therapies and combinations reflects individualized strategies in action.
The discovery of KRAS inhibitors marks a significant breakthrough, with developing drugs like Sotorasib showing promise but also raising challenges with drug resistance over time.

Liquid biopsies present a non-invasive method to analyze circulating tumor DNA (ctDNA) to monitor mutations during treatment.
Techniques like digital droplet PCR enable the tracking of specific mutations, providing insights into treatment efficacy and early signs of resistance.

As the field of cancer therapy continues to evolve, the wealth of genomic data allows for refined treatment strategies that enhance patient outcomes.
While challenges remain, particularly in drug availability and resistance mechanisms, ongoing research is set to improve the prognosis for cancer patients.